RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 KRAS Mutations Predictive of Recurrence in Colon Cancer
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 22
SP 15
OP 16
DO 10.1177/155989771422012
UL http://mdc.sagepub.com/content/14/22/15.2.abstract
AB Codon 12 KRAS mutations are an independent predictor of time to recurrence (TTR) and disease-free survival (DFS) in patients with Stage III colon cancer who received adjuvant treatment. This article presents data from a post hoc analysis of the Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed by Surgery trial [PETACC8; Taieb J et al. Ann Oncol 2014 (abstr O-0024)].